Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure
- 31 October 1985
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 6 (4), 792-796
- https://doi.org/10.1016/s0735-1097(85)80484-8
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- EFFECTS OF DOPAMINE ON THE CEREBRAL BLOOD FLOW IN THE DOGActa Neurologica Scandinavica, 2009
- Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.Circulation, 1984
- Regression of myocardial cellular hypertrophy with vasodilator therapy in chronic congestive heart failure associated with idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 1983
- CARDIOVASCULAR DOPAMINE RECEPTORS: PHYSIOLOGICAL, PHARMACOLOGICAL AND THERAPEUTIC IMPLICATIONSJournal of Autonomic Pharmacology, 1982
- Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat.Proceedings of the National Academy of Sciences, 1982
- Differential systemic arterial and venous actions and consequent cardiac effects of vasodilator drugsProgress in Cardiovascular Diseases, 1982
- Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepinesJournal of Medicinal Chemistry, 1980
- MODULATION OF NORADRENERGIC TRANSMISSION IN THE RABBIT EAR ARTERY BY DOPAMINEBritish Journal of Pharmacology, 1978
- Newer catecholamines for treatment of heart failure and shock: An update on dopamine and a first look at dobutamineProgress in Cardiovascular Diseases, 1977
- Dopamine — Clinical Uses of an Endogenous CatecholamineNew England Journal of Medicine, 1974